Literature DB >> 20376475

Pseudobulbar affect: prevalence and quality of life impact in movement disorders.

Roy E Strowd1, Michael S Cartwright, Michael S Okun, Ihtsham Haq, Mustafa S Siddiqui.   

Abstract

Pseudobulbar affect (PBA) is an affective disinhibition syndrome characterized by sudden, involuntary outbursts of inappropriate crying or laughing. We have previously reported the prevalence of PBA in movement disorders using an interviewer-administered questionnaire that had not been validated. In the current study, a validated self-administered screening instrument, the Center for Neurologic Study-Lability Scale (CNS-LS), was used to study the prevalence of PBA, its association with mood symptoms, and the quality of life impact. Two hundred sixty-nine patients met inclusion criteria (consent, age > 18 years, formal diagnosis, and completion of the CNS-LS). The CNS-LS was used to assess PBA at a cutoff score of 17 (utilized from multiple sclerosis studies). The Beck Depression Inventory (BDI) scale and Parkinson's disease questionnaire (PDQ-39) were used to assess depressive symptoms and quality of life. Logistic regression analysis was used to predict associations with PBA. PBA was prevalent in 7.1% (n = 19) of movement disorder patients. No significant difference in prevalence was observed by patient diagnosis: 7.1% (12/168) in Parkinson's disease (PD), 11.4% (4/35) in essential tremor, 0% (0/13) in dystonia, 0% (0/16) in psychogenic movement disorders, and 10.7% (3/28) in patients with other movement disorders. Patients with PBA had higher BDI depression scores (p < 0.0001) and lower PDQ-39 emotional well-being subscores (p < 0.0001). Patients taking antidepressant medications had significantly higher rates of PBA (p = 0.0008). The prevalence of PBA symptoms was 7.1% in PD and all movement disorders patients. Patients with PBA tend to have more depressive symptoms and poorer quality of life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376475     DOI: 10.1007/s00415-010-5550-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  A clinical overview of pseudobulbar affect.

Authors:  David B Arciniegas
Journal:  Am J Geriatr Pharmacother       Date:  2005

2.  Pathologic laughing and intractable hiccups can occur early in multiple sclerosis.

Authors:  J de Seze; H Zephir; P Hautecoeur; A Mackowiak; M Cabaret; P Vermersch
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

3.  Emotional lability, intrusiveness, and catastrophic reactions.

Authors:  M Haupt
Journal:  Int Psychogeriatr       Date:  1996       Impact factor: 3.878

4.  Influence of motor symptoms upon the quality of life of patients with Parkinson's disease.

Authors:  J C Gómez-Esteban; J J Zarranz; E Lezcano; B Tijero; A Luna; F Velasco; I Rouco; I Garamendi
Journal:  Eur Neurol       Date:  2007-01-10       Impact factor: 1.710

5.  An investigation into some psychiatric aspects of multiple sclerosis.

Authors:  D Surridge
Journal:  Br J Psychiatry       Date:  1969-07       Impact factor: 9.319

6.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Authors:  B R Brooks; R A Thisted; S H Appel; W G Bradley; R K Olney; J E Berg; L E Pope; R A Smith
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

Review 7.  Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands.

Authors:  T Maurice; B P Lockhart
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1997-01       Impact factor: 5.067

8.  Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory.

Authors:  B E Levin; M M Llabre; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

9.  Inappropriate crying and laughing in Parkinson disease and movement disorders.

Authors:  Mustafa S Siddiqui; Hubert H Fernandez; Cynthia W Garvan; Lindsey Kirsch-Darrow; Dawn Bowers; Ramon L Rodriguez; Charles E Jacobson; Christian Rosado; Swetha Vaidyanathan; Kelly D Foote; Michael S Okun
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

10.  Treatment of pathologic laughing and weeping with amitriptyline.

Authors:  R B Schiffer; R M Herndon; R A Rudick
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

View more
  14 in total

1.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

Review 2.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 3.  Diagnostic Approach to Atypical Parkinsonian Syndromes.

Authors:  Nikolaus R McFarland
Journal:  Continuum (Minneap Minn)       Date:  2016-08

4.  Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

Authors:  Michael Fralick; Chana A Sacks; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

Review 5.  Dextromethorphan/quinidine: in pseudobulbar affect.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

6.  Effective use of sertraline for pathological laughing after severe vasospasm due to aneurysmal subarachnoid hemorrhage: case report.

Authors:  Hayato Takeuchi; Kazuhide Iwamoto; Mao Mukai; Tomoaki Fujita; Hitoshi Tsujino; Yoshihiro Iwamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

7.  PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Authors:  Benjamin Rix Brooks; David Crumpacker; Jonathan Fellus; Daniel Kantor; Randall E Kaye
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 8.  Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Authors:  Kerri A Schoedel; Sarah A Morrow; Edward M Sellers
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-26       Impact factor: 2.570

Review 9.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

Review 10.  Pseudobulbar affect: prevalence and management.

Authors:  Aiesha Ahmed; Zachary Simmons
Journal:  Ther Clin Risk Manag       Date:  2013-11-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.